BioSpace News Archive

Odonate Therapeutics, Inc. announced the pricing of an underwritten public offering of 5,614,036 shares of its common stock, offered at a price of $14.25 per share.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $2.10 per share, less underw

MedX Health Corp. ( MDX : TSXV) (“the Company”), announces that there will be a delay in the filing of its Interim Financial Statements and accompanying Management’s Discussion and Analysis, and related CEO and CFO certifications for the Second Quarter ended June 30, 2020 (collectively “Interim Filings”) due to COVID-19 related delays. On May 20, 2020, the Canadian Securities Administrators (CSA) announced that they will

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 2,142,858 shares of common stock of the Company,